ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

More Posts and Webinars

Presentations and publications

Date
Focus
Journal title/Conference
1560579358
June 15, 2019
Avapritinib - SM European Hematology Association (EHA) Annual...
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
Read the full article
1559552740
June 03, 2019
Pralsetinib ASCO 2019: Clinical Activity and...
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer
Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer
Read the full article
1559398538
June 01, 2019
Pralsetinib ASCO 2019: Activity and Tolerability...
Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-altered Thyroid Cancers
Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-altered Thyroid Cancers
Read the full article
1559379949
June 01, 2019
Avapritinib - GIST ASCO 2019: Clinical Activity of...
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
Read the full article
1553970136
March 30, 2019
Pralsetinib American Association for Cancer Research...
Discovery of BLU-667 for RET-driven cancers
Discovery of BLU-667 for RET-driven cancers
Read the full article
1543789289
December 02, 2018
Avapritinib - SM American Society of Hematology (ASH)...
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
Read the full article
1542320453
November 15, 2018
Avapritinib - GIST Connective Tissue Oncology Society (CTOS)...
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)
Read the full article
1540246817
October 22, 2018
Avapritinib - GIST European Society for Medical Onoclogy...
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)
Read the full article
1540246775
October 22, 2018
Avapritinib - GIST European Society for Medical Onoclogy...
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)
Read the full article
1538864323
October 06, 2018
Pralsetinib American Thyroid Association (ATA) Annual Meeting
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)
Read the full article
1538432296
October 01, 2018
Avapritinib - GIST Clinical Cancer Research
Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors
Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors
Read the full article
1538345823
September 30, 2018
BLU-782 American Society for Bone and...
BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
Read the full article
1538000121
September 26, 2018
Pralsetinib IASLC World Conference on Lung Cancer
Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)
Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)
Read the full article
1538000089
September 26, 2018
Pralsetinib Cancer Discovery
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion
Read the full article
1529100833
June 15, 2018
Avapritinib - SM European Hematology Association (EHA) Annual Meeting
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1 Study (poster presentation)
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1 Study (poster presentation)
Read the full article
1523830394
April 15, 2018
Pralsetinib American Association for Cancer Research...
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)
Read the full article
1523830353
April 15, 2018
Pralsetinib Cancer Discovery
Precision targeted therapy with BLU-667 for RET-driven cancers
Precision targeted therapy with BLU-667 for RET-driven cancers
Read the full article
1512943899
December 10, 2017
Avapritinib - SM American Society of Hematology (ASH)...
Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)
Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)
Read the full article
1510351812
November 10, 2017
Avapritinib - GIST Connective Tissue Oncology Society (CTOS)...
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)
Read the full article
1509574157
November 01, 2017
Avapritinib Science Translational Medicine
A precision therapy against cancers driven by KIT/PDGFRA mutations
A precision therapy against cancers driven by KIT/PDGFRA mutations
Read the full article
1509314866
October 29, 2017
Pralsetinib Molecular Targets and Cancer Therapeutics...
BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers
BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers
Read the full article
1505685990
September 17, 2017
Fisogatinib International Liver Cancer Association (ILCA)...
(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)
(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)
Read the full article
1505081139
September 10, 2017
Fisogatinib European Society for Medical Onoclogy...
Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)
Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)
Read the full article
1501452295
July 30, 2017
Pralsetinib World Congress on Thyroid Cancer
BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers
BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers
Read the full article
1496700240
June 05, 2017
Avapritinib - GIST American Society of Clinical Oncology...
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
Read the full article
1491170553
April 02, 2017
Avapritinib - GIST American Association for Cancer Research...
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
Read the full article
1491170447
April 02, 2017
Avapritinib - SM American Association for Cancer Research...
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
Read the full article
1480888795
December 04, 2016
Avapritinib - SM American Society of Hematology (ASH)...
Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)
Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)
Read the full article
1480629552
December 01, 2016
Avapritinib - GIST EORTC – NCI – AACR...
Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
Read the full article
1480456639
November 29, 2016
Fisogatinib Molecular Targets and Cancer Therapeutics...
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)
Read the full article
1461016563
April 18, 2016
Pralsetinib American Association for Cancer Research...
The development of Potent and Selective RET inhibitors
The development of Potent and Selective RET inhibitors
Read the full article
1430516121
May 01, 2015
Research Journal of Clinical Investigation
Targeting cancer with kinase inhibitors
Targeting cancer with kinase inhibitors
Read the full article
1426541525
March 16, 2015
Fisogatinib Cancer Discovery
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Read the full article
1411162202
September 19, 2014
Research Nature Communications
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
Read the full article
1410384400
September 10, 2014
Research Nature Communications
The landscape of kinase fusions in cancer
The landscape of kinase fusions in cancer
Read the full article